Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial

Sponsor
University of Palermo
Study ID
NCT07352514
Status
Recruiting
Apply to this trial

Conditions

  • Chemotherapy-induced Peripheral Neuropathy (CIPN)
  • Neuropathic Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study aims to find out if taking specific dietary supplements (PEA and Scutellaria) along with therapeutic exercise can help reduce nerve pain and damage caused by chemotherapy. Many cancer patients experience nerve-related side effects from chemotherapy, which can significantly impact their quality of life. The study will observe patients who use these supplements and exercises to see if they can effectively manage and improve their nerve health and reduce pain.

Key Dates

First listed
Jan 20, 2026
Start date
Mar 15, 2025
Status verified
Mar 2025
Primary completion
Feb 20, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: PEA + Scutellaria + Therapeutic Exercise
    This group consists of patients who will receive a combination of palmitoylethanolamide (PEA) and Scutellaria along with a standardized therapeutic exercise regimen. The goal is to evaluate the synergistic effects of the nutraceuticals and exercise in reducing neuropathic pain and improving overall nerve health.
  • Arm: Therapeutic Exercise Only
    Patients in this group will participate in a standardized therapeutic exercise program without any additional nutraceutical intervention. This cohort will help determine the efficacy of therapeutic exercise alone in managing symptoms of chemotherapy-induced peripheral neuropathy (CIPN).
  • Arm: PEA + Scutellaria Only
    This group includes patients who will be treated with a combination of PEA and Scutellaria without participating in any structured exercise regimen. The aim is to assess the impact of the nutraceuticals alone on reducing neuropathic pain and improving nerve function.

Primary Outcome Measure

Reduction in Neuropathic Pain Intensity [ Time Frame: Baseline; 30 days after intervention; 60 days after intervention ]

Central Contacts

Related Studies